Skip to main content
. Author manuscript; available in PMC: 2022 Oct 1.
Published in final edited form as: Nat Med. 2022 Mar 21;28(4):814–822. doi: 10.1038/s41591-022-01714-5

Fig. 1. Overall study design.

Fig. 1.

The study incorporates four independent cohorts: the EPIC Norfolk cohort, the Mass General Brigham Biobank (MGBB)-Asthma cohort, the CAMP randomized controlled trial (RCT) and the EMR-Cortisol cohort. The cohorts were utilized sequentially to identify prevalent asthma metabolites, validate significant metabolites, assess the effect of inhaled corticosteroids (ICS) on the steroid metabolites, and evaluate the utility of cortisol as a biomarker of adrenal suppression among asthmatics on ICS. The details of our approach for each cohort are illustrated.

Abbreviations: MGBB-A, Mass General Brigham Biobank (MGBB)-Asthma; RCT, Randomized Controlled Trial; CAMP, Childhood Asthma Management Program; ICS, inhaled corticosteroids; EMR, Electronic Medical health Record; RPDR, Research Patient Data Registry